Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
911417-87-3
Molecular formula
C26H24N6O2
Molecular weight
452.5 g/mol
Drug class
Rho-associated coiled-coil containing protein kinase (ROCK) inhibitorpreferential ROCK2 inhibitor
Mechanism of action
Inhibits ROCK2 more potently than ROCK1. Inhibition modulates pro-inflammatory responses through effects on STAT3/STAT5 phosphorylation and Th17/Treg balance and reduces aberrant profibrotic signalling; these actions are relevant to chronic graft-versus-host disease.
Indications / reported uses
Treatment of adults and paediatric patients aged 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy under the current US product label
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Belumosudil PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Belumosudil Permitted Daily Exposure (PDE) report (the Belumosudil PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Belumosudil Occupational Exposure Limit (OEL) report (the Belumosudil OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.